DE602004028468D1 - Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke - Google Patents
Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zweckeInfo
- Publication number
- DE602004028468D1 DE602004028468D1 DE602004028468T DE602004028468T DE602004028468D1 DE 602004028468 D1 DE602004028468 D1 DE 602004028468D1 DE 602004028468 T DE602004028468 T DE 602004028468T DE 602004028468 T DE602004028468 T DE 602004028468T DE 602004028468 D1 DE602004028468 D1 DE 602004028468D1
- Authority
- DE
- Germany
- Prior art keywords
- prophylactic
- mhc class
- immune responses
- therapeutic purposes
- attachment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47939303P | 2003-06-17 | 2003-06-17 | |
PCT/US2004/019546 WO2005002621A2 (en) | 2003-06-17 | 2004-06-17 | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004028468D1 true DE602004028468D1 (de) | 2010-09-16 |
Family
ID=33563795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004028468T Active DE602004028468D1 (de) | 2003-06-17 | 2004-06-17 | Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050079152A1 (de) |
EP (3) | EP2356999A1 (de) |
JP (2) | JP5127224B2 (de) |
AT (1) | ATE476196T1 (de) |
AU (1) | AU2004253479B9 (de) |
CA (1) | CA2529057A1 (de) |
DE (1) | DE602004028468D1 (de) |
DK (1) | DK1635863T3 (de) |
ES (1) | ES2350043T3 (de) |
MX (1) | MXPA05013973A (de) |
PL (1) | PL1635863T3 (de) |
WO (1) | WO2005002621A2 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
ATE464907T1 (de) | 1999-02-17 | 2010-05-15 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
NZ518999A (en) * | 1999-11-19 | 2002-12-20 | Csl Ltd | Vaccine compositions |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
MXPA05004588A (es) * | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c. |
US20040235770A1 (en) * | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
AU2005265182B2 (en) * | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
WO2006009919A2 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CA2592922A1 (en) | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
AU2005321905A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass CD+4 cells in the induction of an immune response |
PL1833506T3 (pl) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
US20060165711A1 (en) * | 2004-12-29 | 2006-07-27 | Bot Adrian I | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
US8084592B2 (en) * | 2005-06-17 | 2011-12-27 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
EP1896498B1 (de) * | 2005-06-17 | 2014-12-24 | MannKind Corporation | Epitopanaloge |
ES2413079T3 (es) * | 2005-06-17 | 2013-07-15 | Mannkind Corporation | Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral |
NZ565311A (en) * | 2005-07-07 | 2009-10-30 | Pfizer | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
EP1792627A1 (de) * | 2005-12-05 | 2007-06-06 | ImVisioN AG | Eine Intralymphatische Transduktion Allergen (ITAG) enthaltende Zusammensetzung zur Verwendung in der Modulation des Immunsystems |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
WO2007085266A1 (en) * | 2006-01-30 | 2007-08-02 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
JP5566687B2 (ja) | 2006-06-15 | 2014-08-06 | ノバルティス アーゲー | アジュバントを使用しない複数回投与ワクチン接種レジメン |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
US20100144845A1 (en) * | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
CN103736086A (zh) | 2007-02-15 | 2014-04-23 | 曼康公司 | 用于增强t细胞应答的方法 |
EP2361930A3 (de) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimere von peptide-mhc komplexen und deren verwendung in borrelia infektionskrankheiten |
EP2462947B1 (de) * | 2007-03-26 | 2019-03-13 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Von PRAME abstammende Peptide und immunogene Zusammensetzungen damit |
WO2008124632A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
WO2009003493A2 (en) * | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
EP3424525A1 (de) | 2007-10-12 | 2019-01-09 | Massachusetts Institute Of Technology | Impfstoffnanotechnologie |
US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
WO2010009735A2 (en) * | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2606601A (en) | 1948-12-14 | 1952-08-12 | Knoll Associates | Chair having a back rest in the form of a shell-like body |
WO1998058956A2 (en) * | 1997-06-23 | 1998-12-30 | Ludwig Institute For Cancer Research | Methods for inducing an immune response involving prime-boost protocols |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
ATE325619T1 (de) | 1997-07-10 | 2006-06-15 | Mannkind Corp | Vorrichtung zur induktion einer ctl-antwort |
US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
EP1808180A3 (de) * | 1999-10-22 | 2010-12-22 | Sanofi Pasteur Limited | Modifiziertes GP 100 und Verwendung dafür |
US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
US6773695B2 (en) * | 2000-10-05 | 2004-08-10 | Mannkind Corporation | Modulation of allergic response |
JP2005505242A (ja) | 2001-03-07 | 2005-02-24 | マンカインド コーポレイション | 癌用抗新生血管系調製物 |
US20030072764A1 (en) * | 2001-04-05 | 2003-04-17 | O'hagan Derek | Mucosal boosting following parenteral priming |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
US7076244B2 (en) | 2001-07-23 | 2006-07-11 | Research In Motion Limited | System and method for pushing information to a mobile device |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
DE60238864D1 (de) * | 2001-11-07 | 2011-02-17 | Mankind Corp | Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption |
CA2467486A1 (en) * | 2001-11-30 | 2003-06-12 | Isis Innovation Limited | Vaccine |
US20040180354A1 (en) * | 2002-09-06 | 2004-09-16 | Simard John J.L. | Epitope sequences |
WO2004110485A1 (en) * | 2003-06-13 | 2004-12-23 | Palmowski Michael J | Materials and methods for improved vaccination |
US9469902B2 (en) | 2014-02-18 | 2016-10-18 | Lam Research Corporation | Electroless deposition of continuous platinum layer |
US9814289B2 (en) | 2015-04-08 | 2017-11-14 | Otter Products, Llc | Protective folio case for an electronic device |
EP3636238B1 (de) | 2018-10-12 | 2021-04-28 | Liko Research & Development AB | Tore mit übergangsrampen für deckenhubschienen |
-
2004
- 2004-06-17 EP EP10180566A patent/EP2356999A1/de not_active Ceased
- 2004-06-17 CA CA002529057A patent/CA2529057A1/en not_active Abandoned
- 2004-06-17 AU AU2004253479A patent/AU2004253479B9/en not_active Ceased
- 2004-06-17 AT AT04776760T patent/ATE476196T1/de active
- 2004-06-17 EP EP10171754.4A patent/EP2246067B1/de not_active Not-in-force
- 2004-06-17 WO PCT/US2004/019546 patent/WO2005002621A2/en active Application Filing
- 2004-06-17 ES ES04776760T patent/ES2350043T3/es active Active
- 2004-06-17 PL PL04776760T patent/PL1635863T3/pl unknown
- 2004-06-17 EP EP04776760A patent/EP1635863B1/de not_active Not-in-force
- 2004-06-17 DK DK04776760.3T patent/DK1635863T3/da active
- 2004-06-17 MX MXPA05013973A patent/MXPA05013973A/es active IP Right Grant
- 2004-06-17 US US10/871,707 patent/US20050079152A1/en not_active Abandoned
- 2004-06-17 JP JP2006517407A patent/JP5127224B2/ja not_active Expired - Fee Related
- 2004-06-17 DE DE602004028468T patent/DE602004028468D1/de active Active
-
2012
- 2012-09-10 JP JP2012198859A patent/JP2013028619A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2246067B1 (de) | 2017-02-15 |
EP1635863B1 (de) | 2010-08-04 |
EP2246067A2 (de) | 2010-11-03 |
CA2529057A1 (en) | 2005-01-13 |
AU2004253479A1 (en) | 2005-01-13 |
EP2356999A1 (de) | 2011-08-17 |
PL1635863T3 (pl) | 2011-01-31 |
WO2005002621A2 (en) | 2005-01-13 |
WO2005002621A3 (en) | 2005-08-04 |
AU2004253479B9 (en) | 2011-10-06 |
MXPA05013973A (es) | 2006-03-02 |
EP1635863A2 (de) | 2006-03-22 |
JP2007523863A (ja) | 2007-08-23 |
ES2350043T3 (es) | 2011-01-17 |
DK1635863T3 (da) | 2010-11-22 |
JP5127224B2 (ja) | 2013-01-23 |
AU2004253479B2 (en) | 2011-09-01 |
EP2246067A3 (de) | 2011-07-13 |
JP2013028619A (ja) | 2013-02-07 |
US20050079152A1 (en) | 2005-04-14 |
ATE476196T1 (de) | 2010-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004028468D1 (de) | Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke | |
SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
ATE501726T1 (de) | Zusammensetzung mit immunogenen mikroteilchen | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
ATE481108T1 (de) | Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen | |
WO2005037190A3 (en) | Multiplex vaccines | |
NI200800193A (es) | Anticuerpos humanos anti-il-23, composiciones, métodos y usos. | |
CY1114690T1 (el) | Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων | |
ATE419008T1 (de) | Adjuvante zusammensetzung und anwendungsverfahren dafür | |
DE602004024542D1 (de) | Untereinheit-impfstoff gegen das respiratorische synzytialvirus | |
NO20071188L (no) | Humaniserte anti-cMet-antagonister | |
EA201290199A1 (ru) | Способы и композиции для получения сквалена с применением дрожжей | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
CY1108211T1 (el) | Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη | |
BRPI0520330A2 (pt) | adjuvante a base de ácido polinosìnico-policitidìlico | |
MY150706A (en) | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
DK1328547T3 (da) | Identifikation og modifikation af immundominante epitoper i polypeptider | |
DE60330708D1 (de) | Impfstoff gegen das west-nile-virus | |
WO2007078879A3 (en) | Lipopeptide compositions and methods of use thereof | |
ATE529123T1 (de) | Synthetische glykolipopeptide als impfstoffe | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
ATE471990T1 (de) | Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln | |
EA200301151A1 (ru) | Вакцина против натуральной оспы | |
ATE422196T1 (de) | Substituierte cyclohexene | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа |